Generics 23

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Sugammadex manufacturers

23 products found

Filters

23 products found

sugammadex

Vials 100 mg/ml - 2 ml, 5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
MAs available in
France , Germany , Italy , Spain
Comments
DCP approved
Manufacturer #276
This company is a global manufacturer and distributor of high-quality generic medicines, with a mission to make these medicines accessible to patients worldwide. It operates in several regions, including Europe and Latin America, and emphasizes strong partnerships within the pharmaceutical industry to expand its reach. The company is committed to sustainability and transparency, following Environmental, Social, and Governance (ESG) principles. They regularly engage in major industry events, highlighting their dedication to networking and maintaining a leading position in the market for generic medications.

Manufacturer usually replies in 1 days

sugammadex

Solution for injection 200 mg/2 ml, 500 mg/5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP, Greece
Unavailable markets
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czech Republic , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Kosovo , Latvia , Lithuania , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Spain , Sweden , United Kingdom , Vietnam
Available for
Distribution only
Comments
Product is not available for Europe
Manufacturer #298
This company is a global pharmaceutical and commercial organization that has been operating for over five decades. It specializes in injectable and prescription drug products, medical devices, and food supplements. Their manufacturing facilities are EU and US GMP approved. They have a strong presence in international markets, especially in Europe, North America, and Asia. The company also prides itself on its commitment to research and development of new products, particularly in the field of monoclonal antibodies. This commitment has earned them recognition and awards for their innovation and manufacturing excellence.

Manufacturer usually replies in 1 days

sugammadex

Vials, lyophilized injection 100 mg/ml - 2 ml, 5 ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #419

The manufacturer based in Europe, has decades of experience in the industry. They focus on a diverse range of products, including prescription drugs, over-the-counter medications, and medical devices. Their portfolio covers a variety of therapeutic areas, with key focuses on cardiovascular health, oncology, and pain management. The manufacturer holds numerous patents for their innovative products and adheres to strict GMP standards for both the European Union and the United States. They distribute their products across key regions in Europe, North America, and other international markets. Their production lines include solid oral dosage forms, injectables, and liquids, offering a wide range of treatment options for patients.

Want to see all 23 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Sugammadex

Sugammadex is a medication prescribed in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. It is the first selective relaxant binding agent (SRBA) in general anesthesia. Usage of the aminosteroid non-depolarizing neuromuscular-blocking agents such as vecuronium or rocuronium results in the neuromuscular blockade. Sugammadex is a unique and novel cyclodextrin. Termed a neuromuscular reversal drug, it is the first in a new class of selective relaxant binding agents, which reverse neuromuscular blockade. Sugammadex is effective in reversing moderate or deep cases of neuromuscular blockade. Doctors around the world are looking forward to sugammadex eliminating many of the shortcomings of the general anesthetic practice, specifically in the context of antagonism to rocuronium and other aminosteroid muscle relaxants.
Sugammadex is sold under the brand name Bridion. Merck pharm now owns and sells Sugammdex. However, Organon pharmaceutical company at the Newhouse Research Site in Scotland discovered Sugammdex but Organon was bought by Schering-Plough in 2007. Schering-Plough later merged with Merck in 2009. While Sugammadex got approval for use in the European Union in 2008, the US Food and Drug Administration initially rejected Schering-Plough’s New Drug Application for Sugammadex in 2008. However, it was eventually approved for sales in the United States in 2015.

Forms and Dose

Sugammadex is both available and administered as a single bolus injection. For reversing the neurotransmission blockage by rocuronium and vecuronium, the standard adult dose is 4 mg per kilo of body weight. If spontaneous recovery of the twitch response has reached 1 to 2 post-tetanic counts and there are no twitch responses to train-of-four stimulation, the recommended adult dose is 2 mg per kilo of body weight is recommended if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation. For reversing Rocuronium effects only, the recommended adult dose is 16 mg per kilo if there is a clinical need to reverse neuromuscular blockade soon within 3 minutes of administration of a single dose of 1.2 mg per kilo.

The price of Sugammadex

In the USA, consumers have to pay around $1,103 for a supply of 20 milliliters for an intravenous solution (100 mg/mL). and in Australia, the cost of a 200mg vial of Sugammadex varies from A$45 to 195, depending on the brand.

How does Sugammadex work?

Sugammadex actions in the body deactivate rocuronium. It does this encapsulating the free molecule to form a stable complex. Sugammadex exerts its effect by forming very tight complexes at a 1:1 ratio with aminosteroid muscle relaxants creating intermolecular forces, thermodynamic bonds, and hydrophobic interactions. To make a tight sugammadex–rocuronium complex. This complex has a very high association rate and a very low dissociation rate. This results in a reduction in free rocuronium plasma concentration. So it creates a gradient between the tissue compartment and plasma so that the free rocuronium moves from tissue to plasma, with a reduction in nicotinic receptor occupancy at the Neuro-Muscular Junction.

Finding Sugammadex Manufacturers and Suppliers:

The process of finding trusted Sugammadex manufacturers and Sugammadex suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. It is an easy to use online platform to grow your business opportunities.
The robust search engine makes it convenient to search for manufacturers and suppliers of Sugammadex. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier.

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible